AGF Management Ltd. raised its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 8.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 607,064 shares of the biopharmaceutical company's stock after purchasing an additional 45,901 shares during the quarter. AGF Management Ltd.'s holdings in Bristol-Myers Squibb were worth $34,336,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in the business. Fairway Wealth LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $28,000. Avantax Planning Partners Inc. raised its holdings in shares of Bristol-Myers Squibb by 2.8% during the fourth quarter. Avantax Planning Partners Inc. now owns 63,361 shares of the biopharmaceutical company's stock worth $3,584,000 after purchasing an additional 1,705 shares during the period. GC Wealth Management RIA LLC lifted its position in shares of Bristol-Myers Squibb by 3.0% in the 4th quarter. GC Wealth Management RIA LLC now owns 8,239 shares of the biopharmaceutical company's stock worth $466,000 after buying an additional 239 shares during the last quarter. Donaldson Capital Management LLC grew its position in shares of Bristol-Myers Squibb by 61.7% during the 4th quarter. Donaldson Capital Management LLC now owns 59,395 shares of the biopharmaceutical company's stock valued at $3,359,000 after buying an additional 22,653 shares during the last quarter. Finally, SoundView Advisors Inc. acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth about $214,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.
In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,823 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was purchased at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the acquisition, the executive vice president now owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.09% of the company's stock.
Several equities analysts have recently commented on the company. Leerink Partnrs raised Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a report on Tuesday, November 12th. Bank of America reaffirmed a "neutral" rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Citigroup upped their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Leerink Partners raised Bristol-Myers Squibb from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $55.00 to $73.00 in a report on Tuesday, November 12th. Finally, Daiwa America upgraded Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, November 13th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $57.86.
Read Our Latest Stock Analysis on BMY
Shares of NYSE BMY traded down $1.69 during mid-day trading on Wednesday, reaching $59.83. The company had a trading volume of 10,809,797 shares, compared to its average volume of 11,667,687. The stock has a fifty day moving average of $57.62 and a two-hundred day moving average of $55.38. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33. The company has a market capitalization of $121.40 billion, a price-to-earnings ratio of -13.54, a PEG ratio of 2.07 and a beta of 0.43. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25.
Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. As a group, equities research analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be issued a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a yield of 4.15%. Bristol-Myers Squibb's dividend payout ratio is currently -56.11%.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Before you consider Bristol-Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol-Myers Squibb wasn't on the list.
While Bristol-Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.